# AvenCell Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avencell-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.avencell.com
- Total disclosed funding: $112M
- Latest round: Series B (Oct 22, 2024)
- Investors on record: 6

## About

AvenCell Therapeutics, Inc., based in the US, focuses on developing advanced immunotherapies targeting challenging cancers through innovative CAR-T technology, aiming to improve patient outcomes and treatment safety.Founded in 2021 and headquartered in Watertown, US, AvenCell Therapeutics, Inc. specializes in immunotherapy solutions. The company has successfully raised USD 112.00 mn in its most recent Series B funding round on October 22, 2024, led by Novo Holdings, with participation from various investors including Blackstone Life Sciences Advisors and F-Prime Capital. The total amount raised thus far is USD 112.00 mn, reflecting strong investor interest in its proprietary therapies targeting hematologic malignancies and autoimmune diseases.AvenCell Therapeutics specializes in next-generation immunotherapies designed to address hard-to-treat cancers, primarily through its proprietary Universal Switchable CAR and Allogeneic platforms. These innovative therapies leverage advanced technology to enhance the controllability of CAR-T reactivity, ensuring sustained anti-tumor activity while reducing the risks associated with T-effector cell exhaustion and immune suppression. The company's switchable on/off mechanism utilizes universal effector cells combined with Targeting Modules (TMs) for precise targeting of cancer antigens, which is crucial for minimizing adverse effects like cytokine release syndrome (CRS). AvenCell's products aim to provide safer and more effective treatment options for patients in various geographical markets, including North America, Europe, and specific regions in Asia, focusing on delivering improved therapeutic outcomes for patients with limited treatment options.AvenCell Therapeutics generates revenue primarily through partnerships and collaborations with healthcare institutions, biotechnology firms, and academic entities focused on cancer treatment advancements. These partnerships often involve co-development agreements and clinical trial collaborations where AvenCell's proprietary therapies may be integrated into broader treatment regimens. The company’s flagship offerings, including its Universal Switchable CAR technology, are positioned for use in clinical settings, where pricing structures may include transaction models based on successful outcomes in therapy or milestone achievements in research and development phases. This creates a framework for B2B transactions, aligning the company’s innovative therapies with the needs of healthcare providers and research institutions dedicated to improving patient care in oncology.In October 2024, AvenCell Therapeutics raised USD 112 mn through its Series B funding round, aimed at expanding clinical validation of its Universal Switchable CAR-T cell therapy platform targeting hematologic malignancies and autoimmune diseases. The company plans to introduce new product developments within the next 12-18 months, enhancing its offerings in the oncology space. Furthermore, AvenCell is targeting expansion into additional markets in Europe and specific regions in Asia by 2025, leveraging the recent funding to support these initiatives.

## Funding rounds

- Series B, Oct 22, 2024, $112M — Novo Holdings, Eight Roads Ventures, F-Prime Capital, Piper Heartland Healthcare Capital, Blackstone Life Sciences Advisors, NYBC Ventures

## Investors

- Novo Holdings — Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- Piper Heartland Healthcare Capital — Series B
- Blackstone Life Sciences Advisors — Series B
- NYBC Ventures (https://capitalatlas.ai/funds/nybc-ventures) — Series B